SAR447971 First-in-human Study
Condition(s) studied
Investigational drug(s) / intervention(s)
SAR447971: Pharmaceutical form: Tablet Route of administration: Oral
Placebo: Pharmaceutical form: Tablet Route of administration: Oral
Study summary
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.
MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants.
MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants.
Number of participants The total expected number of healthy participants is approximately 102 and the total number of HS participants is expected to be approximately 20.
* SAD20411 will enroll up to 54 participants
* MAD20412 will enroll up to 48 participants
* MAD24339 will enroll up to 20 participants
Duration of study The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.
Eligibility
Primary outcome measure(s)
- SAD20411: Incidence of treatment emergent adverse events (TEAEs) — Day 1 to Day 15
- SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis) — Day 1 to Day 15
- SAD20411: Incidence of clinically significant abnormalities in vital signs — Day 1 to Day 15
- SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF) — Day 1 to Day 15
- MAD20412: Incidence of treatment emergent adverse events (TEAEs) — Day 1 to Day 29
- MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis) — Day 1 to Day 29
- MAD20412: Incidence of clinically significant abnormalities in vital signs — Day 1 to Day 29
- MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF) — Day 1 to Day 29
- MAD24339: Incidence of treatment emergent adverse events (TEAEs) — Day 1 to Day 42
- MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis) — Day 1 to Day 42
- MAD24339: Incidence of clinically significant abnormalities in vital signs — Day 1 to Day 42
- MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF) — Day 1 to Day 42
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Investigational Site Number: 5280001 | Leiden | Netherlands | Recruiting |
More Sanofi trials in the Netherlands
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07629336 on ClinicalTrials.gov ↗ ← All trials in the Netherlands